Estimated dates:(date of event), (date of implant).Udi # - the udi # could not be provided because the part and lot numbers were not reported.The device was not returned for analysis.A review of the lot history record and complaint history of the reported lot could not be conducted because the lot and part number were not provided.Based on the reported information, a definitive cause for the reported stent shortening and/or elongation could not be determined.There is no indication of a product quality issue with respect to the design, manufacture, or labeling of the device.Literature attachment: "comparative outcomes of supera interwoven nitinol vs bare nitinol stents for the treatment of femoropopliteal disease: insights from the xlpad registry".The adverse patient effects referenced are being filed under a separate medwatch report #.The vision and absolute stents referenced are filed under separate medwatch report numbers.(b)(6).
|
It was reported through a research article identifying supera, absolute, and vision stents that may be related to the following: death, restenosis, target vessel/limb revascularization, stent fracture, stent elongation, and stent compression.Details are listed in the attached article, titled, "comparative outcomes of supera interwoven nitinol vs bare nitinol stents for the treatment of femoropopliteal disease: insights from the xlpad registry".
|